![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MT2A |
Gene summary for MT2A |
![]() |
Gene information | Species | Human | Gene symbol | MT2A | Gene ID | 4502 |
Gene name | metallothionein 2A | |
Gene Alias | MT-2 | |
Cytomap | 16q13 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | P02795 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
4502 | MT2A | GSM4909277 | Human | Breast | Precancer | 7.29e-11 | 9.12e-01 | 0.0177 |
4502 | MT2A | GSM4909285 | Human | Breast | IDC | 6.52e-14 | -6.14e-01 | 0.21 |
4502 | MT2A | GSM4909294 | Human | Breast | IDC | 1.49e-04 | 2.32e-01 | 0.2022 |
4502 | MT2A | GSM4909296 | Human | Breast | IDC | 3.86e-04 | -2.13e-01 | 0.1524 |
4502 | MT2A | GSM4909297 | Human | Breast | IDC | 2.02e-14 | 3.81e-01 | 0.1517 |
4502 | MT2A | GSM4909299 | Human | Breast | IDC | 1.79e-06 | 3.90e-01 | 0.035 |
4502 | MT2A | GSM4909308 | Human | Breast | IDC | 2.11e-08 | -4.87e-01 | 0.158 |
4502 | MT2A | GSM4909309 | Human | Breast | IDC | 1.47e-09 | 4.06e-01 | 0.0483 |
4502 | MT2A | GSM4909311 | Human | Breast | IDC | 5.75e-25 | 5.29e-02 | 0.1534 |
4502 | MT2A | GSM4909312 | Human | Breast | IDC | 9.38e-04 | -1.47e-01 | 0.1552 |
4502 | MT2A | GSM4909319 | Human | Breast | IDC | 1.59e-40 | 1.90e-01 | 0.1563 |
4502 | MT2A | GSM4909321 | Human | Breast | IDC | 6.37e-17 | -5.57e-01 | 0.1559 |
4502 | MT2A | ctrl6 | Human | Breast | Precancer | 8.04e-04 | 3.42e-01 | -0.0061 |
4502 | MT2A | brca1 | Human | Breast | Precancer | 8.78e-14 | -6.04e-01 | -0.0338 |
4502 | MT2A | brca2 | Human | Breast | Precancer | 1.44e-29 | 5.24e-01 | -0.024 |
4502 | MT2A | brca3 | Human | Breast | Precancer | 7.33e-50 | 7.14e-01 | -0.0263 |
4502 | MT2A | brca7 | Human | Breast | Precancer | 2.31e-04 | 6.79e-01 | -0.009 |
4502 | MT2A | brca10 | Human | Breast | Precancer | 4.26e-02 | 3.27e-01 | -0.0029 |
4502 | MT2A | M1 | Human | Breast | IDC | 5.08e-03 | -3.95e-01 | 0.1577 |
4502 | MT2A | M5 | Human | Breast | IDC | 4.73e-02 | -6.86e-01 | 0.1598 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064751 | Liver | Cirrhotic | internal protein amino acid acetylation | 65/4634 | 160/18723 | 6.66e-06 | 1.04e-04 | 65 |
GO:00183931 | Liver | Cirrhotic | internal peptidyl-lysine acetylation | 64/4634 | 158/18723 | 8.75e-06 | 1.29e-04 | 64 |
GO:001657011 | Liver | Cirrhotic | histone modification | 154/4634 | 463/18723 | 1.92e-05 | 2.57e-04 | 154 |
GO:00165731 | Liver | Cirrhotic | histone acetylation | 61/4634 | 152/18723 | 1.97e-05 | 2.62e-04 | 61 |
GO:00987547 | Liver | Cirrhotic | detoxification | 60/4634 | 152/18723 | 4.09e-05 | 4.86e-04 | 60 |
GO:00469164 | Liver | Cirrhotic | cellular transition metal ion homeostasis | 48/4634 | 115/18723 | 4.51e-05 | 5.30e-04 | 48 |
GO:2000756 | Liver | Cirrhotic | regulation of peptidyl-lysine acetylation | 30/4634 | 63/18723 | 6.83e-05 | 7.74e-04 | 30 |
GO:00712487 | Liver | Cirrhotic | cellular response to metal ion | 73/4634 | 197/18723 | 7.73e-05 | 8.54e-04 | 73 |
GO:003105611 | Liver | Cirrhotic | regulation of histone modification | 59/4634 | 152/18723 | 8.28e-05 | 9.02e-04 | 59 |
GO:004851111 | Liver | Cirrhotic | rhythmic process | 103/4634 | 298/18723 | 8.47e-05 | 9.19e-04 | 103 |
GO:0043967 | Liver | Cirrhotic | histone H4 acetylation | 31/4634 | 67/18723 | 1.03e-04 | 1.06e-03 | 31 |
GO:00712417 | Liver | Cirrhotic | cellular response to inorganic substance | 81/4634 | 226/18723 | 1.21e-04 | 1.20e-03 | 81 |
GO:1901983 | Liver | Cirrhotic | regulation of protein acetylation | 34/4634 | 77/18723 | 1.53e-04 | 1.46e-03 | 34 |
GO:005105211 | Liver | Cirrhotic | regulation of DNA metabolic process | 114/4634 | 359/18723 | 1.48e-03 | 9.85e-03 | 114 |
GO:00712766 | Liver | Cirrhotic | cellular response to cadmium ion | 19/4634 | 40/18723 | 1.49e-03 | 9.87e-03 | 19 |
GO:0035065 | Liver | Cirrhotic | regulation of histone acetylation | 23/4634 | 54/18723 | 3.02e-03 | 1.72e-02 | 23 |
GO:00712805 | Liver | Cirrhotic | cellular response to copper ion | 14/4634 | 28/18723 | 3.40e-03 | 1.89e-02 | 14 |
GO:00064791 | Liver | Cirrhotic | protein methylation | 61/4634 | 181/18723 | 4.13e-03 | 2.21e-02 | 61 |
GO:00082131 | Liver | Cirrhotic | protein alkylation | 61/4634 | 181/18723 | 4.13e-03 | 2.21e-02 | 61 |
GO:00165711 | Liver | Cirrhotic | histone methylation | 49/4634 | 141/18723 | 4.90e-03 | 2.56e-02 | 49 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0497812 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
hsa0497813 | Breast | IDC | Mineral absorption | 13/867 | 60/8465 | 6.73e-03 | 3.42e-02 | 2.56e-02 | 13 |
hsa0497821 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
hsa0497831 | Breast | DCIS | Mineral absorption | 13/846 | 60/8465 | 5.48e-03 | 2.81e-02 | 2.07e-02 | 13 |
hsa0497814 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
hsa0497815 | Prostate | BPH | Mineral absorption | 20/1718 | 60/8465 | 1.22e-02 | 3.61e-02 | 2.23e-02 | 20 |
hsa049782 | Stomach | CAG with IM | Mineral absorption | 12/640 | 60/8465 | 1.52e-03 | 1.01e-02 | 7.10e-03 | 12 |
hsa049783 | Stomach | CAG with IM | Mineral absorption | 12/640 | 60/8465 | 1.52e-03 | 1.01e-02 | 7.10e-03 | 12 |
hsa049784 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
hsa049785 | Stomach | CSG | Mineral absorption | 11/633 | 60/8465 | 4.40e-03 | 2.53e-02 | 1.82e-02 | 11 |
hsa049786 | Stomach | CAG | Mineral absorption | 8/368 | 60/8465 | 4.18e-03 | 2.94e-02 | 2.36e-02 | 8 |
hsa049787 | Stomach | CAG | Mineral absorption | 8/368 | 60/8465 | 4.18e-03 | 2.94e-02 | 2.36e-02 | 8 |
hsa049788 | Stomach | SIM | Mineral absorption | 11/465 | 60/8465 | 3.61e-04 | 3.41e-03 | 2.74e-03 | 11 |
hsa049789 | Stomach | SIM | Mineral absorption | 11/465 | 60/8465 | 3.61e-04 | 3.41e-03 | 2.74e-03 | 11 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MT2A | SNV | Missense_Mutation | c.17N>T | p.Ser6Phe | p.S6F | P02795 | protein_coding | deleterious(0) | possibly_damaging(0.855) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD | |
MT2A | SNV | Missense_Mutation | c.41N>T | p.Thr14Ile | p.T14I | P02795 | protein_coding | tolerated(0.13) | benign(0.121) | TCGA-D1-A0ZS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
MT2A | SNV | Missense_Mutation | rs149120520 | c.158C>T | p.Ala53Val | p.A53V | P02795 | protein_coding | deleterious(0.04) | benign(0.14) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
MT2A | SNV | Missense_Mutation | novel | c.161C>T | p.Ser54Leu | p.S54L | P02795 | protein_coding | tolerated(0.16) | benign(0.001) | TCGA-SJ-A6ZI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MT2A | SNV | Missense_Mutation | novel | c.28N>T | p.Gly10Cys | p.G10C | P02795 | protein_coding | deleterious(0) | probably_damaging(0.952) | TCGA-05-4424-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Targeted Molecular therapy | erlotinib | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
4502 | MT2A | NA | PARACETAMOL | ACETAMINOPHEN | 9570328 | |
4502 | MT2A | NA | ETHANOL | ALCOHOL | 1733046 |
Page: 1 |